Hospitalized patients with heart failure (HF) undergoing bedside glucose monitoring with subcutaneous insulin orders were retrospectively identified over 2 years. Hypoglycaemia was defined as any glucose value <3.9 mmol/L (70 mg/dL) within 24 hours of admission (Hypo 1day ) or throughout the hospitalization (Hypo T ) or any glucose value <2.2 mmol/L (40 mg/dL) throughout the hospitalization (Hypo Severe ). A total of 13 424 patients were included, of whom 2484 had HF. Patients with HF were more likely to have Hypo 1day (9.1% vs 7.0%, P = .0003), Hypo T (28% vs 18.5%, P < .0001), or Hypo Severe (3.4% vs 2.1%, P = .0001). After controlling for other variables, the odds of Hypo 1day were similar between the HF and non-HF groups (odds ratio 
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[OR] 1.14, 95% CI 0.94-1.39, P = .18, fully adjusted model), slightly lower for Hypo T DM is an independent predictor of mortality in patients with HF. 1 Hypoglycaemia is a complication of DM that may lead to adverse cardiovascular events, including abnormalities in coagulation and inflammation, hypokalaemia, repolarization abnormalities, endothelial dysfunction and activation of sympathoadrenal responses. [2] [3] [4] Hypoglycaemia is particularly concerning in patients with HF because they are predisposed to arrhythmias and ischaemic events. Experts recommend relaxed glucose targets for patients with significant comorbidities and an individualized approach based on the perceived risk of hypoglycaemia. 5 These efforts are complicated by the fact that glucose control has not been well characterized in this population.
Hypoglycaemia is common in hospitalized patients with DM, particularly in those treated with insulin. 6 Many factors contribute to hypoglycaemia among hospitalized patients, including increasing age, higher insulin doses, basal insulin, mistiming of insulin administration, lower body weight, decreased renal function, and changes in diet or medications. 7 Hypoglycaemia in the hospital is associated with longer length of stay, increased inpatient and 1-year mortality, and increased costs. 8 In ambulatory settings, HF is associated with increased risk of severe hypoglycaemia. 9 It is unclear whether HF plays a direct role in the incidence of hypoglycaemia or whether hypoglycaemia confers risk of poor outcomes in patients with HF.
The objective of the present study was to assess whether the risk of iatrogenic hypoglycaemia and relationship with mortality differed among a large population of hospitalized patients with or without HF exacerbation.
2 | METHODS In-hospital mortality and DM-related diagnoses (ICD-9 codes of 250.xx) for each patient were collected.
| Patient selection

| Glucose management
At the study institution, patients with DM and hyperglycaemia are managed with subcutaneous basal-bolus insulin. Orders for capillary glucose monitoring four times daily accompany all subcutaneous insulin orders. Meters are downloaded with exact time stamps at least daily to the electronic medical record.
| Analysis
Continuous variables were reported as mean (SD) for normally distributed variables and median (interquartile range) for non-normally distributed variables. Differences between groups were determined with the unpaired Student's t test for normally distributed variables or Wilcoxon rank-sum for non-normal distributions. Dichotomous variables were reported as number (percentage) and differences between groups were determined using Fisher's exact test. P values <.05 were considered statistically significant. Additional models analysing hospital mortality as dependent variables and hypoglycaemia as the primary independent variable were created, and interactions between HF and hypoglycaemia were assessed. Analyses were performed using JMP 10.0 software.
3 | RESULTS
| Patient characteristics
A total of 21 105 admissions met the inclusion criteria. After elimination of 7681 repeat hospitalizations, 13 424 unique admissions were analysed. Study population demographics are detailed in Table S1 , Supporting Information.
Admission glucose and mean glucose at 24 and 72 hours were lower in the HF than in the non-HF group (Table S2 , Supporting Information). Hypo 1day and Hypo T were more common in the HF group than in the non-HF group (Hypo 1day 9.1 vs 7.0%, P = .0003; Hypo T 28.0 vs 18.5%, P < .0001). Hypo Severe was more common for those in the HF group (3.4 vs 2.1%, P = .0001). There was no interaction by HF status for any of these analyses.
| Relationship between HF and hypoglycaemia
| DISCUSSION
In this manuscript, the odds of hypoglycaemia within the first 24 hours of admission and severe hypoglycaemia throughout the admission were similar between patients with and without HF. The odds of overall hypoglycaemia were lower in the HF group after controlling for other variables; thus, the risk of hypoglycaemia in hospitalized patients with HF seems more likely to be attributable to other known risk factors.
Heart failure is characterized by profound neuroendocrine and autonomic disturbances, 11 and it is possible that this affects the incidence or manifestations of hypoglycaemia 12 ; however, the autonomic responses to hypoglycaemia in the setting of HF are unknown. The present findings are consistent with those of a small study that included hospitalized patients, in which HF was associated with a lower risk of hypoglycaemia, captured using continuous glucose monitoring during algorithmic adjustment of basal bolus insulin. 13 The lack of increased risk of hypoglycaemia attributable to HF may have important implications for targeting prevention, recognition and treatment strategies.
Importantly, it is unknown whether hypoglycaemia risk translates to outcomes in patients with HF. In the present study, the association between hypoglycaemia and mortality was similar in the HF and non-HF groups, supporting a more generalized hypoglycaemia mitigation strategy, although this study is unable to prove causation. In the ADVANCE study, there was no clear direct relationship between hypoglycaemia and mortality and therefore it was unclear whether hypoglycaemia was a marker of severe illness or a causal factor. 3 In the ACCORD trial, severe hypoglycaemia did not explain the excess risk of mortality observed with tight glycaemic control. 4 In patients with HF, higher HbA1c level has been associated with increased mortality, 14 while other data support a paradoxical relationship between HbA1c and outcomes, 15 indicating that the risk of hypoglycaemia may mitigate benefits of lower HbA1c. These studies could not determine whether the low HbA1c is harmful, or even whether hypoglycaemia plays a role.
The present study has several limitations, owing to its retrospective nature. The population was defined via electronic medical record data Model 16 (restricted to patients with a diabetes diagnosis code): includes age, gender, race, BMI*, surgery service, length of stay*, admission glucose*, admission creatinine*, β blockade, basal insulin. * denotes log-transformed values.
and thus the aetiology and severity of HF and cause of death were unknown. A diagnosis of diabetes was not an inclusion criterion because of the limitations of using diagnosis codes for identifying at-risk patients and because patients undergoing glucose monitoring with insulin orders were considered a more relevant population. HbA1c values were not available in most patients. Interventions for HF or DM were not standardized and the details of management were unavailable. Medication classes that may affect risks of hypoglycaemia or mortality, such as inotropes, diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were not analysed, as the doses of these medications change frequently during a hospitalization for HF. In the present analysis, we included established clinical factors used by other authors. 9 It might be worthwhile for future studies to investigate the effects of these medication classes on hypoglycaemia and mortality during HF admissions. The exact insulin doses for each patient could not be analysed because they could not be adequately extracted from the dataset. In addition, we were unable to assess episodes of hypoglycaemia prior to admission. Despite these limitations, the present analysis is consistent with other inpatient data, and is the most comprehensive study of hypoglycaemia in hospitalized patients with HF to date.
In summary, the present study indicates that HF is associated with similar or lower risk of hypoglycaemia in hospitalized patients after controlling for other variables. Moreover, hypoglycaemia is associated with increased hospital mortality, regardless of HF.
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